Last year, Roche group revenue edged 1% higher to 63.3 billion Swiss francs, the company reported, beating market expectations of 63.2 billion francs, while core operating profit gained 1% to 22.2 billion Swiss francs, just shy of the average analyst estimate of 22.4 billion francs.
As a result, the stock has fallen about 11% over the past three years, lagging its key global rivals.The onus to reinvigorate the pipeline will be on chief executive officer-designate Thomas Schinecker, who was previously Roche's head of diagnostics and due to be promoted to group CEO in March. Family-controlled Roche said on Thursday that Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, would succeed Anderson.